Pharmafile Logo

Surface oncology

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

Springer Nature Oncologists survey report 202

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

Springer Nature

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

Full Panel Discussion: Closing The Gaps In Patient-Centricity

On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

Medscape Education Global

- PMLiVE

Kite and Refuge Biotechnologies join to develop potential treatments for blood cancer

The agreement bolsters Kite’s expertise in synthetic biology for oncology

- PMLiVE

ICR research shows blood tests could help guide the treatment for children’s cancer

Using liquid biopsies to monitor patients could determine how well treatment is working

- PMLiVE

Medscape Medical Affairs are PMEA Finalists in Three Categories

The Pharmaceutical Market Excellence Awards (PMEA) have announced that Medscape Medical Affairs is a finalist in their 2022 awards for their entry Transatlantic Exchanges: Driving Therapeutic Innovation in Oncology for...

Medscape Medical Affairs

- PMLiVE

Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies

- PMLiVE

Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes

Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal

- PMLiVE

Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

An improvement in radiographic progression-free survival was demonstrated

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links